RandomIsed sTudy of Physiologic cArdiac stimuLation in patIents With Atrio-ventricular Conduction Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

Study objective is to assess whether stimulation of the conduction system reduces cardiac decompensation events in patient follow-up, and how applicable this is in clinical practice and also to determine the impact of the studied interventions in terms of quality of life and cost-effectiveness for the treatment of patients with atrioventricular block. 1260 adult patients who are candidates for pacemaker implantation for the treatment of atrioventricular conduction disease will be randomised to stimulation of the conduction system or to the conventional stimulation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients with AV block in either sinus rhythm (SR) or permanent atrial tachycardia/atrial fibrillation (AT/AF), or with slow AV conduction during AT/AF, or undergoing AV node ablation + ventricular stimulation

male and female

acquired informed consent

Disqualifiers

Class I indication to Implantable Cardioverter Defibrillator (ICD) or to Cardiac Resynchronization Therapy (CRT)

Ejection Fraction < 35%

Life expectancy < 2 years

Participation in another clinical trial which might impact on the study outcome

Trial design

Design model

Parallel

Treatments tested in this trial

  • Conduction System Pacing (CSP)

    Procedure/Surgery

    CSP occurs at the left endocardic surface of the interventricular septum hence specifically designed delivery catheters are used to advance the ventricular lead across the septum until its left-sided edge, where the Left Bundle is located. To determine whether CSP has been achieved, a standard 12-lead electrocardiogram (ECG) is continuously recorded.

  • Right Ventricular (RV) Pacing

    Procedure/Surgery

    RV pacing delivered either at the RV apex or RV septum. RV pacing is delivered by single chamber or dual chamber pacemakers depending on patients' rhythm (sinus or AT/AF) according to well-established clinical practice as described in the EHRA recommendtions

Treatment groups

1,260 Participants
are divided into 2 treatment groups
Group A: Conduction System Pacing (CSP)Experimental treatment 1 intervention
Group B: Conventional System Pacing/Right Ventricular (RV) PacingActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Heart failure

composite endponit of: number of HF events, HF hospitalizations and HF non-pharmacological interventions

Time frame
36 months after the PM implant

Secondary outcomes

1

number of HF events

number of HF events

Time frame
36 months after the PM implant
2

HF hospitalizations

HF hospitalizations

Time frame
36 months after the PM implant
3

HF non-pharmacological interventions

HF non-pharmacological interventions

Time frame
36 months after the PM implant

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.